Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis

References

• Pakozdi A, Pyne D, Sheaff M, Rajakariar R. Utility of a repeat renal biopsy in lupus nephritis: a single centre experience. Nephrol Dial Transplant. 2018;33(3):507–513. doi:10.1093/ndt/gfx019
   Web of Science ®Google Scholar
• Kon T, Yamaji K, Sugimoto K, et al. Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol. 2010;20(2):168–177. doi:10.3109/s10165-009-0260-3
   PubMed Web of Science ®Google Scholar
• Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174–194. doi:10.1016/j.autrev.2012.08.018
   PubMed Web of Science ®Google Scholar
• Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006;45(9):1144–1147. doi:10.1093/rheumatology/kel039
   Web of Science ®Google Scholar
• Quintana LF, Jayne D. Sustained remission in lupus nephritis: still a hard road ahead. Nephrol Dial Transplant. 2016;31(12):2011–2018. doi:10.1093/ndt/gfv381
   Web of Science ®Google Scholar
• Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011–1020. doi:10.1177/0961203320932219
   PubMed Web of Science ®Google Scholar
• Sabucedo AJ, Contreras G. ESKD, transplantation, and dialysis in lupus nephritis. Semin Nephrol. 2015;35(5):500–508. doi:10.1016/j.semnephrol.2015.08.011
   Web of Science ®Google Scholar
• Zhang L, Lee G, Liu X, et al. Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int. 2016;89(6):1337–1345. doi:10.1016/j.kint.2016.02.014
   PubMed Web of Science ®Google Scholar
• Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24(8):181–197.
   PubMed Web of Science ®Google Scholar
• Scheschowitsch K, Leite JA, Assreuy J. New insights in glucocorticoid receptor signaling-more than just a ligand-binding receptor. Front Endocrinol (Lausanne). 2017;8:16. doi:10.3389/fendo.2017.00016
   PubMed Web of Science ®Google Scholar
• Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247. doi:10.1038/nri.2017.1
   PubMed Web of Science ®Google Scholar
• Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):133–144. doi:10.1038/s41584-020-0371-y
   PubMed Web of Science ®Google Scholar
• Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42–54. doi:10.1016/j.tem.2017.10.010
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum. 1998;41(5):761–767. doi:10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–745. doi:10.1016/0140-6736(92)92292-N
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–557. doi:10.7326/0003-4819-125-7-199610010-00003
   PubMed Web of Science ®Google Scholar
• Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137. doi:10.1186/s12916-016-0673-8
   PubMed Web of Science ®Google Scholar
• Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, Manns B. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus. 2010;19(5):628–633. doi:10.1177/0961203309356292
   Web of Science ®Google Scholar
• Fischer-Betz R, Chehab G, Sander O, et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol. 2012;39(11):2111–2117. doi:10.3899/jrheum.120537
   PubMed Web of Science ®Google Scholar
• Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484–1493. doi:10.1177/0961203311418269
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280–1286. doi:10.1136/annrheumdis-2012-202844
   PubMed Web of Science ®Google Scholar
• Tedeschi B, Arnaud L, Hie M, Mathian A, Amoura Z. Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. Ann Rheum Dis. 2014;73(2):474–475. doi:10.1136/annrheumdis-2013-204385
   Web of Science ®Google Scholar
• Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95(1):219–231. doi:10.1016/j.kint.2018.08.025
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13(2):206–214. doi:10.1016/j.autrev.2013.10.013
   PubMed Web of Science ®Google Scholar
• Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14(10):875–879. doi:10.1016/j.autrev.2015.05.011
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi:10.1136/annrheumdis-2019-215089
   PubMed Web of Science ®Google Scholar
• Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: executive summary. Rheumatology (Oxford). 2018;57(1):14–18. doi:10.1093/rheumatology/kex291
   Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. doi:10.1002/acr.21664
   PubMed Web of Science ®Google Scholar
• Pons-Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549–1557. doi:10.1136/annrheumdis-2018-213512
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713–723. doi:10.1136/annrheumdis-2020-216924
   PubMed Web of Science ®Google Scholar
• Lightstone L. Minimising steroids in lupus nephritis–will B cell depletion pave the way? Lupus. 2013;22(4):390–399. doi:10.1177/0961203313476155
   Web of Science ®Google Scholar
• Lightstone L, Doria A, Wilson H, Ward FL, Larosa M, Bargman JM. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev. 2018;17(1):4–10. doi:10.1016/j.autrev.2017.11.002
   PubMed Web of Science ®Google Scholar
• Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018;5(1):e000234. doi:10.1136/lupus-2017-000234
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020;29(10):1155–1167. doi:10.1177/0961203320930099
   PubMed Web of Science ®Google Scholar
• Yang X, Sherwin CM, Yu T, Yellepeddi VK, Brunner HI, Vinks AA. Pharmacokinetic modeling of therapies for systemic lupus erythematosus. Expert Rev Clin Pharmacol. 2015;8(5):587–603. doi:10.1586/17512433.2015.1059751
   PubMed Web of Science ®Google Scholar
• Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 1987;47(10):2723–2726.
   Web of Science ®Google Scholar
• Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long? Clin Rev Allergy Immunol. 2011;40(3):181–191. doi:10.1007/s12016-009-8196-0
   Web of Science ®Google Scholar
• Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006;119(4):355 e325–333. doi:10.1016/j.amjmed.2005.08.045
   Web of Science ®Google Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–680. doi:10.7326/0003-4819-150-10-200905190-00004
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2002;29(10):2129–2135.
   PubMed Web of Science ®Google Scholar
• Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum. 1999;42(6):1274–1280. doi:10.1002/1529-0131(199906)42:6<1274::AID-ANR26>3.0.CO;2-B
   Web of Science ®Google Scholar
• Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004;50(7):2202–2210. doi:10.1002/art.20338
   PubMed Web of Science ®Google Scholar
• Singh G, Saxena N, Aggarwal A, Misra R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol. 2007;34(4):731–733.
   PubMed Web of Science ®Google Scholar
• van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, Hahlen K, Dohle GR, van den Heuvel-eibrink MM. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009;52(1):108–112. doi:10.1002/pbc.21780
   Web of Science ®Google Scholar
• Sabbour MS, Osman LM. Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis. Br J Dermatol. 1979;100(2):113–125. doi:10.1111/j.1365-2133.1979.tb05548.x
   Web of Science ®Google Scholar
• Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614–619. doi:10.1056/NEJM198603063141004
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–2131. doi:10.1002/art.10461
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–64. doi:10.1136/ard.2008.102533
   PubMed Web of Science ®Google Scholar
• Attia DHS, Eissa M, Samy LA, Khattab RA. Influence of glutathione S transferase A1 gene polymorphism (−69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis. Clin Rheumatol. 2021;40(2):753–762. doi:10.1007/s10067-020-05276-0
   Web of Science ®Google Scholar
• Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2–8. doi:10.1191/0961203305LU2109OA
   PubMed Web of Science ®Google Scholar
• Joy MS, Hilliard T, Hu Y, et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009;29(1):7–16. doi:10.1592/phco.29.1.7
   PubMed Web of Science ®Google Scholar
• Mino Y, Naito T, Matsushita T, et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther Drug Monit. 2008;30(6):656–661. doi:10.1097/FTD.0b013e31818b8244
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–1895. doi:10.1056/NEJMoa1014460
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–1112. doi:10.1681/ASN.2008101028
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–1162. doi:10.1056/NEJM200010193431604
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford). 2004;43(3):377–380. doi:10.1093/rheumatology/keh012
   Web of Science ®Google Scholar
• Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis. 1998;32(2):318–322. doi:10.1053/ajkd.1998.v32.pm9708620
   PubMed Web of Science ®Google Scholar
• Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74–87. doi:10.1053/j.ajkd.2012.08.041
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78. doi:10.3899/jrheum.100130
   PubMed Web of Science ®Google Scholar
• Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford). 2009;48(8):944–952. doi:10.1093/rheumatology/kep120
   Web of Science ®Google Scholar
• Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22(7):1933–1942. doi:10.1093/ndt/gfm066
   PubMed Web of Science ®Google Scholar
• Rovin BH, Parikh SV, Hebert LA, et al. Lupus nephritis: induction therapy in severe lupus nephritis–should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013;8(1):147–153. doi:10.2215/CJN.03290412
   Web of Science ®Google Scholar
• Walsh M, Solomons N, Lisk L, Jayne DR. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis. 2013;61(5):710–715. doi:10.1053/j.ajkd.2012.11.042
   Web of Science ®Google Scholar
• Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152–160. doi:10.1038/ki.2009.412
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Hong Kong Nephrology Study G. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076–1084. doi:10.1681/ASN.2004080686
   PubMed Web of Science ®Google Scholar
• Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 2010;12(6):R208. doi:10.1186/ar3184
   PubMed Web of Science ®Google Scholar
• Fassbinder T, Saunders U, Mickholz E, et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthritis Res Ther. 2015;17:92. doi:10.1186/s13075-015-0603-8
   Web of Science ®Google Scholar
• Mejia-Vilet JM, Arreola-Guerra JM, Cordova-Sanchez BM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R. Comparison of lupus nephritis induction treatments in a Hispanic population: a single-center cohort analysis. J Rheumatol. 2015;42(11):2082–2091. doi:10.3899/jrheum.150395
   Web of Science ®Google Scholar
• Dall’Era M, Solomons N, Federico R, Truman M. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus. 2019;28(5):591–596. doi:10.1177/0961203319842924
   PubMed Web of Science ®Google Scholar
• Kittanamongkolchai W, Rukrung C, Supasiri T, et al. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus. 2013;22(7):727–732. doi:10.1177/0961203313486949
   PubMed Web of Science ®Google Scholar
• Luszczynska P, Pawinski T. Therapeutic drug monitoring of mycophenolic acid in lupus nephritis: a review of current literature. Ther Drug Monit. 2015;37(6):711–717. doi:10.1097/FTD.0000000000000223
   Web of Science ®Google Scholar
• Yap DYH, Tam CH, Yung S, et al. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrol Dial Transplant. 2020;35(5):810–818. doi:10.1093/ndt/gfy284
   PubMed Web of Science ®Google Scholar
• Luszczynska P, Pawinski T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur J Clin Pharmacol. 2019;75(3):371–379. doi:10.1007/s00228-018-2599-x
   Web of Science ®Google Scholar
• Alexander S, Fleming DH, Mathew BS, et al. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit. 2014;36(4):423–432. doi:10.1097/FTD.0000000000000031
   PubMed Web of Science ®Google Scholar
• Pourafshar N, Karimi A, Wen X, et al. The utility of trough mycophenolic acid levels for the management of lupus nephritis. Nephrol Dial Transplant. 2019;34(1):83–89. doi:10.1093/ndt/gfy026
   Web of Science ®Google Scholar
• Kiyokawa T, Hanaoka H, Iida H, et al. High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis. Mod Rheumatol. 2020;30(3):517–524. doi:10.1080/14397595.2019.1623435
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64(8):753–767. doi:10.1007/s00228-008-0478-6
   PubMed Web of Science ®Google Scholar
• Kaballo BG, Ahmed AE, Nur MM, Khalid IO, Abu-Aisha H. Mycophenolate mofetil versus azathioprine for maintenance treatment of lupus nephritis. Saudi J Kidney Dis Transpl. 2016;27(4):717–725. doi:10.4103/1319-2442.185233
   PubMed Web of Science ®Google Scholar
• Tamirou F, D’Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526–531. doi:10.1136/annrheumdis-2014-206897
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29(4 Pt 2):601–605.
   PubMed Web of Science ®Google Scholar
• Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149(4):907–917 e907. doi:10.1053/j.gastro.2015.06.002
   PubMed Web of Science ®Google Scholar
• Roy LM, Zur RM, Uleryk E, Carew C, Ito S, Ungar WJ. Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics. 2016;17(6):633–656. doi:10.2217/pgs.16.12
   Web of Science ®Google Scholar
• Velo-Garcia A, Ntatsaki E, Isenberg D. The safety of pharmacological treatment options for lupus nephritis. Expert Opin Drug Saf. 2016;15(8):1041–1054. doi:10.1080/14740338.2016.1182496
   PubMed Web of Science ®Google Scholar
• McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3(1):89–98. doi:10.1517/14622416.3.1.89
   PubMed Web of Science ®Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. doi:10.1136/annrheumdis-2015-208840
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69(12):2083–2089. doi:10.1136/ard.2010.131995
   PubMed Web of Science ®Google Scholar
• Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED. Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2015;42(8):1392–1400. doi:10.3899/jrheum.141650
   Web of Science ®Google Scholar
• Nee R, Rivera I, Little DJ, Yuan CM, Abbott KC. Cost-utility analysis of mycophenolate mofetil versus azathioprine based regimens for maintenance therapy of proliferative lupus nephritis. Int J Nephrol. 2015;2015:917567. doi:10.1155/2015/917567
   Google Scholar
• Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db84
   PubMed Web of Science ®Google Scholar
• Scalea JR, Levi ST, Ally W, Brayman KL. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol. 2016;12(3):333–342. doi:10.1586/1744666X.2016.1123093
   PubMed Web of Science ®Google Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80(3 Pt 2):S40–45. doi:10.1006/clin.1996.0140
   PubMedGoogle Scholar
• Kato A, Chustz RT, Ogasawara T, et al. Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J Immunol. 2009;182(11):7233–7243. doi:10.4049/jimmunol.0801375
   Web of Science ®Google Scholar
• Moroni G, Ponticelli C. Synthetic pharmacotherapy for lupus nephritis. Expert Opin Pharmacother. 2017;18(2):175–186. doi:10.1080/14656566.2016.1276563
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123–139. doi:10.1007/s40262-013-0120-3
   PubMed Web of Science ®Google Scholar
• Zavada J, Sinikka Pesickova S, Rysava R, et al. Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus. 2014;23(1):69–74. doi:10.1177/0961203313511555
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001–2010. doi:10.1681/ASN.2007121272
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18–26. doi:10.7326/M14-1030
   PubMed Web of Science ®Google Scholar
• Sakai R, Kurasawa T, Nishi E, et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 2018;27(2):273–282. doi:10.1177/0961203317719148
   PubMed Web of Science ®Google Scholar
• Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467–1472. doi:10.1093/ndt/gfr484
   PubMed Web of Science ®Google Scholar
• Yap DY, Yu X, Chen XM, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17(4):352–357. doi:10.1111/j.1440-1797.2012.01574.x
   Web of Science ®Google Scholar
• Ikeuchi H, Hiromura K, Takahashi S, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618–625. doi:10.3109/14397595.2013.844397
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30–36. doi:10.1136/annrheumdis-2014-206456
   PubMed Web of Science ®Google Scholar
• Kamanamool N, Ingsathit A, Rattanasiri S, et al. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus. 2018;27(4):647–656. doi:10.1177/0961203317739131
   Web of Science ®Google Scholar
• Zhang H, Liu Z, Zhou M, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28(12):3671–3678. doi:10.1681/ASN.2017030263
   PubMed Web of Science ®Google Scholar
• Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes–mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010;25(12):3939–3948. doi:10.1093/ndt/gfq322
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135–1141. doi:10.1177/0961203313502864
   PubMed Web of Science ®Google Scholar
• Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27:961203318758505.
   Web of Science ®Google Scholar
• Jesus D, Rodrigues M, da Silva JAP, Ines L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27:961203318758508.
   Web of Science ®Google Scholar
• Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun Rev. 2004;3(3):188–192. doi:10.1016/j.autrev.2003.08.002
   PubMed Web of Science ®Google Scholar
• Garcia-Carrasco M, Mendoza-Pinto C, Macias Diaz S, et al. P-glycoprotein in autoimmune rheumatic diseases. Autoimmun Rev. 2015;14(7):594–600. doi:10.1016/j.autrev.2015.02.006
   PubMed Web of Science ®Google Scholar
• Ragab SM, Soliman MA. P-glycoprotein-1 functional activity in CD5+CD7+ and CD20+ lymphocytes in systemic lupus erythematosus children: relation to disease activity, complications and steroid response. Egypt J Immunol. 2013;20(2):101–115.
   Google Scholar
• Kansal A, Tripathi D, Rai MK, Agarwal V. Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. Clin Rheumatol. 2016;35(2):341–349. doi:10.1007/s10067-015-3079-7
   PubMed Web of Science ®Google Scholar
• Picchianti-Diamanti A, Rosado MM, Scarsella M, Lagana B, D’Amelio R. P-glycoprotein and drug resistance in systemic autoimmune diseases. Int J Mol Sci. 2014;15(3):4965–4976. doi:10.3390/ijms15034965
   Web of Science ®Google Scholar
• Singh JA, Hossain A, Kotb A, et al. Treatments for lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2016;43(10):1801–1815. doi:10.3899/jrheum.160041
   Web of Science ®Google Scholar
• Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015;24(14):1520–1528. doi:10.1177/0961203315595131
   Web of Science ®Google Scholar
• Tian J, Luo Y, Wu H, Long H, Zhao M, Lu Q. Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. Lupus Sci Med. 2018;5(1):e000253. doi:10.1136/lupus-2017-000253
   Web of Science ®Google Scholar
• Hannah J, Casian A, D’Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev. 2016;15(1):93–101. doi:10.1016/j.autrev.2015.09.006
   PubMed Web of Science ®Google Scholar
• Kraaij T, Bredewold OW, Trompet S, et al. TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Sci Med. 2016;3(1):e000169. doi:10.1136/lupus-2016-000169
   PubMedGoogle Scholar
• Kuglstatter A, Mueller F, Kusznir E, et al. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 2):119–123. doi:10.1107/S0907444910051905
   PubMedGoogle Scholar
• Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003;22(12):1343–1352. doi:10.1016/S1053-2498(03)00033-0
   PubMed Web of Science ®Google Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996;5(Suppl 1):S11–15. doi:10.1177/0961203396005001041
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–269. doi:10.1007/s10787-015-0239-y
   PubMed Web of Science ®Google Scholar
• Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–729. doi:10.1038/nrneph.2011.150
   PubMed Web of Science ®Google Scholar
• Wu SF, Chang CB, Hsu JM, et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther. 2017;19(1):183. doi:10.1186/s13075-017-1393-y
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8(9):522–533. doi:10.1038/nrrheum.2012.106
   PubMed Web of Science ®Google Scholar
• An N, Chen Y, Wang C, et al. Chloroquine autophagic inhibition rebalances Th17/Treg-mediated immunity and ameliorates systemic lupus erythematosus. Cell Physiol Biochem. 2017;44(1):412–422. doi:10.1159/000484955
   PubMedGoogle Scholar
• Gao R, Wu W, Wen Y, Li X. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. Int Urol Nephrol. 2017;49(7):1233–1241. doi:10.1007/s11255-017-1574-2
   PubMed Web of Science ®Google Scholar
• Yang YZ, Liu LJ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in immunoglobulin A nephropathy. Am J Nephrol. 2018;47(3):145–152. doi:10.1159/000487330
   PubMed Web of Science ®Google Scholar
• Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflamm. 2018;2018:3424136. doi:10.1155/2018/3424136
   PubMed Web of Science ®Google Scholar
• Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res Ther. 2006;8(2):R42. doi:10.1186/ar1897
   Web of Science ®Google Scholar
• Lopez P, Gomez J, Prado C, Gutierrez C, Suarez A. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol. 2008;35(8):1559–1566.
   Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16(3):411–419. doi:10.1080/14740338.2017.1269168
   PubMed Web of Science ®Google Scholar
• Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol. 2012;16(1):102–108. doi:10.1007/s10157-011-0520-3
   Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394. doi:10.1016/j.ophtha.2016.01.058
   PubMed Web of Science ®Google Scholar
• Mahon GJ, Anderson HR, Gardiner TA, McFarlane S, Archer DB, Stitt AW. Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy. Curr Eye Res. 2004;28(4):277–284. doi:10.1076/ceyr.28.4.277.27835
   PubMed Web of Science ®Google Scholar
• Shulman S, Wollman J, Brikman S, Padova H, Elkayam O, Paran D. Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists. Lupus. 2017;26(3):277–281. doi:10.1177/0961203316660204
   PubMed Web of Science ®Google Scholar
• Putney JW. TRP, inositol 1,4,5-trisphosphate receptors, and capacitative calcium entry. Proc Natl Acad Sci U S A. 1999;96(26):14669–14671. doi:10.1073/pnas.96.26.14669
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120(1):214–222. doi:10.1172/JCI40231
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–445. doi:10.1182/blood.V83.2.435.435
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 Pt 1):859–866. doi:10.1111/j.1600-6143.2006.01288.x
   PubMed Web of Science ®Google Scholar
• Montalvao F, Garcia Z, Celli S, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest. 2013;123(12):5098–5103. doi:10.1172/JCI70972
   PubMed Web of Science ®Google Scholar
• Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77(4):542–548. doi:10.1097/01.TP.0000112934.12622.2B
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev. 2017;16(6):633–643. doi:10.1016/j.autrev.2017.04.007
   Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi:10.1002/art.34359
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106–111. doi:10.1093/ndt/gfs285
   PubMed Web of Science ®Google Scholar
• Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol. 2006;2(4):221–230. doi:10.1038/ncpneph0133
   Google Scholar
• Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502–1509. doi:10.2215/CJN.01070118
   PubMed Web of Science ®Google Scholar
• Trivin C, Tran A, Moulin B, et al. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J. 2017;10(4):461–469. doi:10.1093/ckj/sfw101
   PubMed Web of Science ®Google Scholar
• Gkrania-Klotsas E, Kumararatne DS. Serious infectious complications after rituximab therapy in patients with autoimmunity: is this the final word? Clin Infect Dis. 2021;72(5):738–742. doi:10.1093/cid/ciaa131
   Web of Science ®Google Scholar
• Md Yusof MY, Vital EM, Buch MH. B cell therapies, approved and emerging: a review of infectious risk and prevention during use. Curr Rheumatol Rep. 2015;17(10):65. doi:10.1007/s11926-015-0539-7
   Web of Science ®Google Scholar
• Dyson JK, Jopson L, Ng S, et al. Improving testing for hepatitis B before treatment with rituximab. Eur J Gastroenterol Hepatol. 2016;28(10):1172–1178. doi:10.1097/MEG.0000000000000689
   Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–1164. doi:10.1001/archneurol.2011.103
   PubMed Web of Science ®Google Scholar
• Stabler S, Giovannelli J, Launay D, et al. Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study. Clin Infect Dis. 2021;72(5):727–737. doi:10.1093/cid/ciaa127
   PubMed Web of Science ®Google Scholar
• Dominguez-Mozo MI, Toledano-Martinez E, Rodriguez-Rodriguez L, Garcia-Montojo M, Alvarez-Lafuente R, Fernandez-Gutierrez B. JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab. Scand J Rheumatol. 2016;45(6):507–511. doi:10.3109/03009742.2015.1135980
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? Drugs. 2009;69(15):2035–2043. doi:10.2165/11318290-000000000-00000
   Web of Science ®Google Scholar
• Sato M, Yamada M, Nakajima M, Miyama Y, Kitayama H. The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies. CEN Case Rep. 2020;9(4):392–394. doi:10.1007/s13730-020-00492-8
   Web of Science ®Google Scholar
• Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford). 2005;44(4):561–562. doi:10.1093/rheumatology/keh533
   Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109. doi:10.1186/ar2506
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang M, Long D, et al. Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients. Autoimmunity. 2020;53(4):192–200. doi:10.1080/08916934.2020.1736049
   PubMed Web of Science ®Google Scholar
• Marcondes F, Scheinberg M. Belimumab in the treatment of systemic lupus erythematous: an evidence based review of its place in therapy. Autoimmun Rev. 2018;17(2):103–107. doi:10.1016/j.autrev.2017.11.013
   Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled Phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–154. doi:10.1177/0961203312469259
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(4):115–121. doi:10.1177/1759720X15588514
   Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-2
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.30613
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128. doi:10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121–131. doi:10.1002/art.41466
   PubMed Web of Science ®Google Scholar
• Ward M, Tektonidou MG. Belimumab as add-on therapy in lupus nephritis. N Engl J Med. 2020;383(12):1184–1185. doi:10.1056/NEJMe2027516
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–2228. doi:10.1056/NEJMoa043731
   PubMed Web of Science ®Google Scholar
• Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–85. doi:10.1191/096120398678919778
   Web of Science ®Google Scholar
• Fessler BJ, Alarcon GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–1480. doi:10.1002/art.21039
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–583. doi:10.1177/0961203306071872
   PubMed Web of Science ®Google Scholar
• Siso A, Ramos-Casals M, Bove A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17(4):281–288. doi:10.1177/0961203307086503
   Web of Science ®Google Scholar
• Pons-Estel GJ, Alarcon GS, McGwin G, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–839. doi:10.1002/art.24538
   PubMed Web of Science ®Google Scholar
• Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62(3):855–862. doi:10.1002/art.27300
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Alarcon GS, Hachuel L, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford). 2012;51(7):1293–1298. doi:10.1093/rheumatology/ker514
   Web of Science ®Google Scholar